Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.

Official Title

A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity. - Males and females of childbearing potential must agree to utilize effective contraception methods. - Ability to understand and sign a written informed consent form.
Exclusion Criteria:
  1. - Females who are pregnant or breastfeeding. - Participation in any other clinical trial without prior approval from the Sponsor. - Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study. - Subjects receiving ongoing therapy with contraindicated drugs.


Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Assistant Professor of Medicine (Infectious Diseases)
Andrew Zolopa

Contact us to find out if this trial is right for you.


Debbie Slamowitz
(650) 723-2804